Maryum Rafique, DO
Physical Medicine & Rehabilitation · Bear, DENPI 1538328869
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,260 of the $5,206 with a category attached, or 81.8%. It is spread thinly across 31 manufacturers, the largest accounting for just 18.4% — the pattern of someone who eats at a lot of different presentations.
Across 236 payments — averaging $22.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$959
- Si-bone, Inc.$786
- Collegium Pharmaceutical, Inc.$510
- Biotronik NRO, Inc.$314
- SPR Therapeutics, Inc$311
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$301
- plus $2K from 25 others
What the payments were for
- Travel & lodging$91017%
- Food & beverage$4,26082%
- Education$361%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 46 | $959 |
| Si-bone, Inc. | 4 | $786 |
| Collegium Pharmaceutical, Inc. | 33 | $510 |
| Biotronik NRO, Inc. | 14 | $314 |
| SPR Therapeutics, Inc | 3 | $311 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 19 | $301 |
| Scilex Pharmaceuticals Inc. | 14 | $271 |
| Nevro Corp. | 11 | $263 |
| Daiichi Sankyo Inc. | 8 | $166 |
| Medtronic(2 entities) | 5 | $126 |
| Biohaven Pharmaceutical Holding Company Ltd. | 16 | $121 |
| Redhill Biopharma Inc. | 8 | $117 |
| Pfizer | 7 | $106 |
| Teva Pharmaceuticals USA, Inc. | 6 | $99 |
| Lilly USA, LLC | 6 | $96 |
| Bioventus LLC | 3 | $72 |
| Biohaven Pharmaceuticals, Inc. | 4 | $71 |
| Saluda Medical Americas, Inc. | 2 | $63 |
| Almatica Pharma LLC | 4 | $55 |
| Biodelivery Sciences International, Inc. | 4 | $53 |
| Shionogi Inc | 3 | $52 |
| AbbVie | 2 | $51 |
| Tersera Therapeutics LLC | 3 | $50 |
| Amgen | 3 | $48 |
| GRT US Holding, Inc. | 2 | $36 |
| Painteq LLC | 1 | $27 |
| AstraZeneca | 1 | $17 |
| Boston Scientific | 1 | $17 |
| IBSA Pharma Inc. | 1 | $16 |
| Foundation Fusion Solutions, LLC | 1 | $16 |
| Globus Medical | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,206 in reported general payments places this provider in the 85th percentile of 32 physical medicine & rehabilitation providers in Delaware.
See all physical medicine & rehabilitation providers in Delaware →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 70 | $63,990 |
| RelistorMethylnaltrexone Bromide | 14 | $32,614 |
| NucyntaTapentadol Hcl | 21 | $19,964 |
| Xtampza ErOxycodone Myristate | 36 | $18,744 |
| LyricaPregabalin | 22 | $14,191 |
| Buprenorphine | 51 | $13,357 |
| OxycontinOxycodone Hcl | 17 | $12,113 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 430 | $11,161 |
| ZtlidoLidocaine | 19 | $10,982 |
| Oxycodone Hcl | 383 | $6,607 |
| MovantikNaloxegol Oxalate | 12 | $6,058 |
| SymproicNaldemedine Tosylate | 11 | $5,008 |
| Diclofenac Sodium | 28 | $4,807 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 205 | $4,246 |
| Pregabalin | 264 | $4,058 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Nucynta, Xtampza Er | $510 | $102,698127 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $301 | $32,61414 claims |
| PfizerLyrica | $106 | $14,19122 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $271 | $10,98219 claims |
| Redhill Biopharma Inc.Movantik | $117 | $6,05812 claims |
| Shionogi IncSymproic | $52 | $5,00811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 32 physical medicine & rehabilitation providers in Delaware.
Other physical medicine & rehabilitation in Bear
- Haresh SampathkumarDover$29K
- Yu ChiuNewark$23K
- Peter CoveleskiLewes$9K
- Jay FreidMilford$8K
- Anthony CucuzzellaNewark$4K
- Lyndon CagampanDover$2K
- Evan CohenNewark$2K
- Sargoon NepaulNewark$2K
- Scott RobertsNewark$2K
- William NewellNewark$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.